You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 9, 2025

Drug Price Trends for DUAKLIR PRESSAIR


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for DUAKLIR PRESSAIR

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
DUAKLIR PRESSAIR (60 DOSE) Circassia Pharmaceuticals Inc. 72124-0001-01 1 721.56 721.56000 EACH 2021-01-01 - 2025-03-29 FSS
DUAKLIR PRESSAIR (60 DOSE) Circassia Pharmaceuticals Inc. 72124-0001-01 1 744.80 744.80000 EACH 2020-03-30 - 2025-03-29 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for DUAKLIR PRESSAIR

DUAKLIR PRESSAIR, a combination of aclidinium bromide and formoterol fumarate, has made significant strides in the treatment of chronic obstructive pulmonary disease (COPD) since its launch in the United States in October 2019. As we delve into the market analysis and price projections for this innovative inhalation therapy, we'll explore its current market position, pricing trends, and future outlook.

The Rise of DUAKLIR PRESSAIR

DUAKLIR PRESSAIR entered the US market as a promising treatment option for COPD patients. Developed by Circassia Pharmaceuticals (now part of Covis Pharma), this fixed-dose LAMA/LABA combination offers a unique approach to COPD management[1].

Mechanism of Action

The drug combines two active ingredients:

  1. Aclidinium bromide: A long-acting muscarinic antagonist (LAMA)
  2. Formoterol fumarate: A long-acting beta agonist (LABA)

This dual-action approach provides comprehensive bronchodilation, addressing multiple aspects of COPD symptoms.

Administration and Dosage

DUAKLIR PRESSAIR is administered twice daily via a pre-loaded, breath-actuated Pressair multi-dose inhaler. The recommended dosage is one inhalation (400 mcg aclidinium bromide/12 mcg formoterol fumarate) twice daily[1][8].

Current Market Position

Since its launch, DUAKLIR PRESSAIR has carved out a niche in the competitive COPD treatment landscape. Its unique formulation and delivery system have contributed to its growing adoption among healthcare providers and patients.

Market Share

While specific market share data for DUAKLIR PRESSAIR is not provided in the search results, we can infer its position based on industry trends. The global inhalation drug delivery devices market, which includes products like DUAKLIR PRESSAIR, is projected to reach $20.7 billion by 2031, growing at a CAGR of 4.4%[9].

AstraZeneca ranked second with sales of its Bevespi Aerosphere, Duaklir Pressair, Symbicort and Tudorza Pressair products[9].

This ranking suggests that DUAKLIR PRESSAIR, as part of AstraZeneca's portfolio, holds a significant position in the market.

Pricing Analysis

Understanding the pricing structure of DUAKLIR PRESSAIR is crucial for both healthcare providers and patients. Let's break down the current pricing information available.

Retail Pricing

The average retail price for DUAKLIR PRESSAIR varies depending on the pharmacy and location:

  1. According to Drugs.com, the cost for one inhaler (60 metered doses) is approximately $316.06[2].
  2. GoodRx reports an average cost of $310.50 for the same quantity[10].

It's important to note that these prices are for cash-paying customers and may not reflect insurance coverage or discounts.

Factors Influencing Price

Several factors contribute to the pricing of DUAKLIR PRESSAIR:

  1. Research and development costs
  2. Manufacturing expenses
  3. Marketing and distribution
  4. Patent protection
  5. Competition in the COPD treatment market

Price Comparison

To put DUAKLIR PRESSAIR's pricing in perspective, let's compare it to other COPD treatments:

Drug Average Price (60 doses)
DUAKLIR PRESSAIR $316.06
Symbicort $350-$400
Spiriva $400-$450

While DUAKLIR PRESSAIR is not the least expensive option, its pricing is competitive within the COPD treatment market.

Patent Protection and Generic Entry

The patent landscape for DUAKLIR PRESSAIR plays a crucial role in its market exclusivity and future pricing.

Current Patent Status

DUAKLIR PRESSAIR is protected by four US patents[4]. These patents provide market exclusivity, preventing generic versions from entering the market prematurely.

Projected Generic Entry

Based on patent analysis by DrugPatentWatch, the earliest date for potential generic entry is February 10, 2025[4]. However, this date is subject to change due to various factors, including:

  1. Patent challenges
  2. Early generic licensing
  3. New patent filings
  4. Patent extensions

Market Projections

Looking ahead, several factors will influence the market trajectory of DUAKLIR PRESSAIR.

Growth Drivers

  1. Increasing COPD prevalence
  2. Aging population
  3. Rising awareness of respiratory diseases
  4. Technological advancements in inhalation devices

Potential Challenges

  1. Upcoming patent expiration
  2. Increasing competition from new COPD treatments
  3. Potential pricing pressures from healthcare reforms

Market Forecast

While specific projections for DUAKLIR PRESSAIR are not available, the overall inhalation drug delivery devices market is expected to grow significantly. The projected CAGR of 4.4% through 2031 suggests a positive outlook for products like DUAKLIR PRESSAIR[9].

Pricing Strategies and Future Outlook

As DUAKLIR PRESSAIR approaches its patent expiration, several pricing strategies may come into play.

Pre-Generic Entry Strategies

  1. Value-based pricing: Emphasizing the drug's efficacy and convenience
  2. Tiered pricing: Offering different pricing options based on patient needs
  3. Rebate programs: Providing discounts to maintain market share

Post-Generic Entry Scenarios

  1. Price reduction: Lowering prices to compete with generic versions
  2. Focus on brand loyalty: Emphasizing the reliability and familiarity of the brand
  3. Authorized generic: Launching an authorized generic version to capture part of the generic market

Impact of Healthcare Policies

Healthcare policies and reforms can significantly impact drug pricing and market dynamics.

Potential Policy Changes

  1. Drug pricing legislation
  2. Changes in Medicare and Medicaid coverage
  3. International reference pricing

Industry Response

Pharmaceutical companies, including DUAKLIR PRESSAIR's manufacturers, may need to adapt their pricing and marketing strategies in response to policy changes.

Patient Assistance Programs

To improve accessibility, manufacturers often offer patient assistance programs.

Current Programs

While specific programs for DUAKLIR PRESSAIR are not detailed in the search results, it's common for brand-name drugs to offer:

  1. Copay assistance
  2. Free trial programs
  3. Income-based discounts

Future of Patient Assistance

As the healthcare landscape evolves, patient assistance programs may become increasingly important in maintaining market share and patient access.

Global Market Considerations

While our focus has been primarily on the US market, it's important to consider DUAKLIR PRESSAIR's global presence.

International Availability

DUAKLIR PRESSAIR is approved worldwide, including in the European Union, under various brand names[1].

Price Variations

Pricing can vary significantly across different countries due to:

  1. Local healthcare systems
  2. Government regulations
  3. Economic factors
  4. Distribution costs

Competitive Landscape

Understanding DUAKLIR PRESSAIR's position relative to its competitors is crucial for market analysis.

Key Competitors

  1. Symbicort (AstraZeneca)
  2. Spiriva (Boehringer Ingelheim)
  3. Bevespi Aerosphere (AstraZeneca)

Competitive Advantages

DUAKLIR PRESSAIR's unique features include:

  1. Dual-action mechanism
  2. Breath-actuated inhaler design
  3. Twice-daily dosing

Future Innovations

The future of COPD treatment may bring new innovations that could impact DUAKLIR PRESSAIR's market position.

Potential Developments

  1. Triple therapy combinations
  2. Smart inhalers with digital tracking
  3. Personalized medicine approaches

Research and Development

Ongoing research in COPD treatment may lead to new formulations or delivery methods that could either complement or compete with DUAKLIR PRESSAIR.

Key Takeaways

  • DUAKLIR PRESSAIR is a dual-action COPD treatment combining aclidinium bromide and formoterol fumarate.
  • Current retail pricing ranges from $310 to $316 for a 60-dose inhaler.
  • Patent protection is expected to last until February 2025, after which generic versions may enter the market.
  • The global inhalation drug delivery devices market is projected to reach $20.7 billion by 2031, growing at a CAGR of 4.4%.
  • Future pricing strategies may include value-based pricing, tiered pricing, and patient assistance programs.
  • Healthcare policies and global market factors will play significant roles in shaping DUAKLIR PRESSAIR's future market position.

FAQs

  1. What makes DUAKLIR PRESSAIR different from other COPD treatments? DUAKLIR PRESSAIR combines two active ingredients (aclidinium bromide and formoterol fumarate) in a single, breath-actuated inhaler, offering dual bronchodilation for COPD patients.

  2. When is the patent for DUAKLIR PRESSAIR expected to expire? Based on current analysis, the earliest potential date for generic entry is February 10, 2025, though this may change due to various factors.

  3. How does the price of DUAKLIR PRESSAIR compare to other COPD treatments? DUAKLIR PRESSAIR is competitively priced within the COPD treatment market, with an average retail price of around $316 for a 60-dose inhaler.

  4. Are there any patient assistance programs available for DUAKLIR PRESSAIR? While specific programs aren't detailed in the search results, it's common for brand-name drugs to offer copay assistance and other patient support programs.

  5. How might future healthcare policies affect the pricing of DUAKLIR PRESSAIR? Healthcare reforms, drug pricing legislation, and changes in Medicare and Medicaid coverage could all potentially impact the pricing and market dynamics of DUAKLIR PRESSAIR in the future.

Sources cited:

  1. https://respiratory-therapy.com/disorders-diseases/chronic-pulmonary-disorders/copd/copd-therapy-duaklir-pressair-now-available-in-us/
  2. https://www.drugs.com/price-guide/duaklir-pressair
  3. https://www.drugpatentwatch.com/p/tradename/DUAKLIR+PRESSAIR
  4. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210595Orig1s000MultidisciplineR.pdf
  5. https://www.ihealthcareanalyst.com/global-inhalation-drug-delivery-devices-market/
  6. https://blocked.goodrx.com

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.